Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882921 · ClinicalTrials.gov registry record
An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
A clinical trial, sponsored by Shire.
- Completed
- Registry status
- 26
- Enrollment target
NCT00882921 is a clinical trial that has completed, run by Shire. The registered enrollment target is 26 participants.
The verdict
NCT00882921 has completed, sponsored by Shire.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effect of anti-idursulfase antibodies on idursulfase safety (measured by infusion related adverse events) between patients who develop anti-idursulfase antibodies and patients who do not after long-term idursulfase enzyme replacement therapy (ERT).
Interventions
- BIOLOGICAL Idursulfase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-10-14 |
| Est. Completion | 2013-02-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882921
The ClinicalTrials.gov registry entry for NCT00882921 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Idursulfase is the first listed.
NCT00882921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882921 about?
NCT00882921 is a clinical study titled "An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients". The objective of this study is to evaluate the effect of anti-idursulfase antibodies on idursulfase safety (measured by infusion related adverse events) between patients who develop anti-idursulfase antibodies and patients who do not after long-term idursulfase enzyme replacement therapy (ERT).
What is the current status of trial NCT00882921?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2008-10-14. Estimated completion is 2013-02-08.
What interventions are being tested in trial NCT00882921?
The interventions under investigation include: Idursulfase (BIOLOGICAL).
Who is sponsoring clinical trial NCT00882921?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.